Download our free ebook: your guide to CRPS filled with incredible knowledge on the condition

CRPS Treatment: pain in both arms for 4 years

General details and patient's info

Age:35 years old at the time of treatment.
Home Country:USA.
Illness duration:4 years prior to the Neridronate Treatment.
Cause:Tear of the left brachial tendon.
Symptoms:Severe 24/7 pain; sensation of being on fire, extreme sensitivity to touch; sensation of being squeezed, swelling, changes in skin temperature. Irritability due to pain and inability to manage even simple daily tasks: any movement triggers pain.
Clinical evaluation:CRPS diagnosis.
Time of treatment:March 2022.

Why the Patient decided to undergo the CRPS Treatment in Italy

The patient’s father found information on Neridronate at the beginning of 2020, and decided to travel there, planning the whole journey together with MTI Patient Care Coordinator. Due to the Covid pandemic however, they both were too worried to travel. They finally came to Italy for the treatment in 2022 when, unfortunately, CRPS had spread from the former left arm to the right one too.

Medical treatment the Patient underwent in Italy

Complex regional pain syndrome (CRPS) is a severely painful and disabling disease for which a multitude of therapeutic interventions have been proposed. In the past two decades, only Bisphosphonates gained credibility. In recent years, more convincing evidence has become available on the use of Parenteral Neridronate. Since 2014, this drug is registered and marketed in Italy for the treatment of CRPS. To date, the only therapeutic schedule that is recognized to be able to confer benefit is the intravenous (IV) administration of 100 mg given 4 times.

4 neridronate infusions (100mg, I.v. in saline Solution 0,9% 250 ml)

See the Official Study on the Oxford Academics website:

4 Pantoprazole infusions; Paracetamol.

2 sessions Neuromuscular Rehabilitation Treatment with Physiotherapist and Osteopath
Rehabilitation therapy is a full body workout which focuses on the general wellbeing of the body, to help the affected limb get back to its normal self.

10 days Light Therapy (in the hotel room, 30+ more minutes each day)
30 minutes or more of usage of the MTI Light Therapy reduces inflammation, increase micro-circulation, relax nerves and muscles, reduces pain transmission, accelerates healing, regenerates cells, and promotes cells activation.

Daily Report

DAY 1: Arrival at the Verona airport, greeted by her Patient Manager, followed by check-in at her Hotel in Vicenza. Briefing focused on the next days.

DAY 2: Rest day in hotel, in contact with her Patient Manager.

DAY 3: Morning pick-up by her Patient Manager, 1st visit with the Rheumatologist Professor, 1st Neridronate infusion and, 1st Rehabilitation session with the 2 specialists.

DAY 4: Morning pick-up by her Patient Manager, 2nd Neridronate infusion.

DAY 5: Morning pick-up by her Patient Manager, 3rd Neridronate infusion. The patient says she feels a bit nauseous, but she can stand it. Lunch with her Patient manager and in the afternoon visit of Padova’s city center.

DAY 6: Morning pick-up by her Patient Manager, 4th Neridronate infusion. 2nd visit with the Rheumatologist Professor and 2nd Rehabilitation session with physiotherapist and osteopathic specialists together.

DAY 7: Rest day.

DAY 8: In the morning visit of Vicenza center with Patient Manager and in the afternoon rest at her hotel.

DAY 9: Day trip to Venice with her Patient Manager. Both the patient and her father are enthusiast to visit this magic town.

DAY 10: Check out and drop-off at Venice Airport by her Patient Manager.

Follow up

June 2023 (2 months after Neridronate treatment): the patient says that her pain level is decreasing and that she overall feels much better.

SEPTEMBER 2023 (6 months after Neridronate treatment): the patient can manage her pain, which decreased after Neridronate infusions. She is working on both her arms mobility.


The patient reported good results after the treatment in Italy. Neridronate works at its best if taken at the CRPS earliest stages. If the patient could have travelled to Italy 2 years before, when she was planned to, she probably would have undergone before the disease spread to both arms, stopping it from happening. It is important to say that Neridronate may lead to remission from CRPS but also helps preventing the spreading of the illness to further limbs.

This is not a medical case study; it merely describes each patient’s journey, and it omits all personal data. The people who redacted it are not doctors but all the facts reported are objective and represent the patient’s reality thanks to the information in our possession. The report is not part of any clinical trials. It was written to provide more information to patients who have made multiple requests for treatment outcomes of cases like theirs.